A Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared with Physician's Best Choice in HER2-Negative Breast Cancer Patients with Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD)

Administered By

Awarded By

Contributors

Start/End

  • October 2, 2019 - October 10, 2024